A detailed history of Wfa Asset Management Corp transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Wfa Asset Management Corp holds 211 shares of GILD stock, worth $19,030. This represents 0.01% of its overall portfolio holdings.

Number of Shares
211
Previous 209 0.96%
Holding current value
$19,030
Previous $14.3 Million 23.32%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$66.59 - $83.99 $133 - $167
2 Added 0.96%
211 $17.7 Million
Q2 2024

Jul 19, 2024

BUY
$63.15 - $72.88 $126 - $145
2 Added 0.97%
209 $14.3 Million
Q1 2024

Apr 18, 2024

BUY
$71.58 - $87.29 $143 - $174
2 Added 0.98%
207 $15.1 Million
Q4 2023

May 24, 2024

BUY
$73.27 - $83.09 $146 - $166
2 Added 0.99%
205 $16.6 Million
Q4 2023

Jan 31, 2024

BUY
$73.27 - $83.09 $146 - $166
2 Added 0.99%
205 $16.6 Million
Q3 2023

May 24, 2024

SELL
$73.94 - $80.67 $295 - $322
-4 Reduced 1.93%
203 $15.2 Million
Q3 2023

Oct 13, 2023

BUY
$73.94 - $80.67 $147 - $161
2 Added 1.0%
203 $15.2 Million
Q2 2023

Oct 13, 2023

BUY
$76.01 - $86.7 $152 - $173
2 Added 1.01%
201 $15.5 Million
Q1 2023

Oct 13, 2023

BUY
$77.31 - $88.08 $154 - $176
2 Added 1.02%
199 $16.5 Million
Q4 2022

Oct 13, 2023

BUY
$62.32 - $89.47 $124 - $178
2 Added 1.03%
197 $16.9 Million
Q3 2022

Oct 13, 2023

BUY
$59.54 - $68.01 $119 - $136
2 Added 1.04%
195 $12.1 Million
Q2 2022

Oct 13, 2023

BUY
$57.72 - $65.01 $115 - $130
2 Added 1.05%
193 $11.9 Million
Q1 2022

Oct 13, 2023

BUY
$57.92 - $72.58 $115 - $145
2 Added 1.06%
191 $11.3 Million
Q4 2021

Oct 13, 2023

BUY
$64.88 - $73.64 $12,262 - $13,917
189 New
189 $13.7 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Wfa Asset Management Corp Portfolio

Follow Wfa Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wfa Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Wfa Asset Management Corp with notifications on news.